USPTO serial 99976312
MYRIAD ONCOLOGY
Reviewed by CopyMark Law Group
Status 819
- Filing date
- Status date
- Registration date
- —
- Examiner
- CHOE, JULIE H
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MYRIAD ONCOLOGY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Salt Lake City, UT, US
Salt Lake City, UT, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joyce M. Ferraro
Joyce M. Ferraro Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd Street, 17th FloorNew York, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Medical test kit related to oncology comprising specimen collection containers in the nature of tubes for the collection of bodily fluids containing cell-free DNA, printed instructions and test forms, materials for transmitting specimens in the nature of envelopes, cardboard boxes, and plastic bags all in the medical field, and printed user information inserts being forms | ACTIVE | Feb 11, 2026 |
| 044 | Medical testing services related to oncology; genetic and genomic testing related to oncology for medical purposes; genetic testing for medical purposes; genetic testing services for diagnostic or treatment purposes; genetic counseling; medical diagnostic testing, monitoring, and reporting services; providing medical diagnostic services, namely, medical analysis services for diagnostic and treatment purposes provided by medical laboratories and medical diagnostic testing; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; medical diagnostic testing for the detection of cancer to assess the presence or absence of residual disease; health assessment services; providing personalized healthcare and medical information, namely, providing medical information and reports; providing medical information, consultancy and advisory services; health evaluation services, namely, performing health assessments and health screening for purposes of determining medical risks and further testing | ACTIVE | May 1, 2024 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 17, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Nov 17, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Nov 16, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Nov 16, 2026 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Nov 16, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 16, 2026 | IUAF | USE AMENDMENT FILED | — |
| Sep 16, 2026 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Sep 16, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 16, 2026 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Sep 16, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| May 26, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 26, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 26, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 26, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 26, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 17, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 20, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 20, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 14, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 19, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 19, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 19, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 19, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 9, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 9, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 9, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 24, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 24, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 24, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 25, 2025 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 25, 2025 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 25, 2025 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 24, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 6, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 6, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 6, 2025 | NWAP | NEW APPLICATION ENTERED | — |